US 12,258,636 B2
Methods for early prediction, treatment response, recurrence and prognosis monitoring of pancreatic cancer
Ruo-Kai Lin, Taipei (TW); and Hsieh-Tsung Shen, Taipei (TW)
Assigned to EG BIOMED CO., LTD., Taipei (TW); and EG BIOMED AU PTY LTD, Melbourne (AU)
Filed by EG BIOMED CO., LTD., Taipei (TW); and EG BIOMED AU PTY LTD, Melbourne (AU)
Filed on Feb. 16, 2024, as Appl. No. 18/444,053.
Claims priority of provisional application 63/485,748, filed on Feb. 17, 2023.
Prior Publication US 2024/0279744 A1, Aug. 22, 2024
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/154 (2013.01)] 23 Claims
 
1. A method for determining an increased risk of pancreatic cancer in a human subject, wherein the method comprises:
(a) extracting (i) cell-free DNA (cfDNA) from a biological sample of the human subject or (ii) genomic DNA from a biological sample from a pancreatic tumor tissue of the human subject, wherein the cfDNA or the genomic DNA comprises the target of ZFP30 DNA;
(b) assaying methylation level of one or more CpG sites of the ZFP30 from the cfDNA or the genomic DNA using methylation-specific polymerase chain reaction (MSP) assay, wherein a pair of ZFP30 methylation-specific primers used in the assay comprises SEQ ID NO: 1 and SEQ ID NO: 2;
(c) comparing the methylation level of step (b) to the methylation level from a control sample without pancreatic cancer; and
(d) determining an increased risk of pancreatic cancer in the human subject based upon a higher methylation level detected in the sample as compared to the control sample.